Michael Coyle

EVP & Group President, Cardiac and Vascular Group

In July, Medtronic, the Dublin-based medical-device company, received U.S. Food and Drug Administration approval for an implantable delivery system to treat patients with pulmonary arterial hypertension. The groundbreaking technology is a win not only for those who suffer from hypertension but also for the company’s Cardiac and Vascular Group, which, under Coyle, has been on a roll with the unveiling of new medical devices. Weeks before the FDA approved the implantable solution, it green-lit a new ventricular assist device developed by Medtronic that helps the heart pump and increase blood flow through the body. For Coyle, a trained engineer who has served as executive vice president with Medtronic and group president of the Cardiac and Vascular Group since 2009, the aggressive innovation has been a lasting key to the company’s success. “This is going to be a very big company,” Coyle told the Securities and Exchange Commission shortly after he was appointed to helm the Cardiac and Vascular Group. “And I think the key is going to be to maintain the intimacy we have with our physician customers as we take advantage of the size and scale we have as a combined organization.”